Journal article icon

Journal article

The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity

Abstract:

Doxorubicin is a commonly used chemotherapeutic agent for the treatment of a range of cancers, but despite its success in improving cancer survival rates, doxorubicin is cardiotoxic and can lead to congestive heart failure. Therapeutic options for this patient group are limited to standard heart failure medications with the only drug specific for doxorubicin cardiotoxicity to reach FDA approval being dexrazoxane, an iron-chelating agent targeting oxidative stress. However, dexrazoxane has fai...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1007/s10557-020-06941-x

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Physiology Anatomy & Genetics
Role:
Author
ORCID:
0000-0001-9136-7518
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
RDM Cardiovascular Medicine
Role:
Author
ORCID:
0000-0002-0780-8905
Publisher:
Springer Publisher's website
Journal:
Cardiovascular Drugs and Therapy Journal website
Volume:
34
Pages:
255-269
Publication date:
2020-02-08
Acceptance date:
2020-01-20
DOI:
EISSN:
1573-7241
ISSN:
0920-3206
Pmid:
32034646
Language:
English
Keywords:
Pubs id:
1086412
Local pid:
pubs:1086412
Deposit date:
2020-02-27

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP